$AMRZ

Gibson Dwight Audley Konrad purchased $244 of AMRZ

Gibson Dwight Audley Konrad purchased 5 shares of Amrize Ltd (AMRZ) at $44.58 on 2026-08-27.

Original reporting
SEC EDGAR · Gibson Dwight Audley Konrad
Published Aug 31, 2026, 7:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 7:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMRZ
Neutral
low confidence
Mentioned
$AMRZ
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZNeutralLow
01

Why it matters

The director's purchase is modest and unlikely to move the stock, but it confirms continued insider ownership.

02

Market read

Limited relevance; only of interest to insiders and very short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions not disclosed yet.

Relevance 4/10Novelty 3/10Timing: after-hours filing on Aug 31

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$AMRZNeutralLow confidence
Context

Director Gibson Dwight Audley Konrad purchased 5 shares for $44.58 each, increasing his stake to 5,199 shares.

Expected impact

No material price movement expected.

Evidence & confidence

The $244 purchase is too small to affect market perception or liquidity.

Market effects

None; the transaction is company‑specific.

None; no broader regional effect.

None

Counterpoint

Even small insider buys can precede larger moves; monitor for follow‑on purchases.

Key entities

  • Amrize Ltd

    Issuer of the securities.

  • Gibson Dwight Audley Konrad

    Director of Amrize Ltd.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.